Indications

Metastatic Colorectal Cancer (mCRC) MVASI® is approved to treat metastatic colorectal cancer (mCRC) for:

  • First- or second-line treatment in combination with intravenous fluorouracil-based chemotherapy... Read More
  • Second-line treatment when used with fluoropyrimidine-based (combined with irinotecan or oxaliplatin) chemotherapy after cancer progresses following a first-line treatment that includes MVASI®
MVASI® is not approved for use after the primary treatment of colon cancer that has not spread to other parts of the body. Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) MVASI®, in combination with carboplatin and paclitaxel, is approved to treat advanced non-squamous non-small cell lung cancer (NSCLC) in people who have not received chemotherapy for their advanced disease. Recurrent Glioblastoma (rGBM) MVASI® is approved to treat recurrent glioblastoma in adults. Metastatic Renal Cell Carcinoma (mRCC) MVASI®, used with interferon alfa, is approved to treat metastatic kidney cancer (mRCC). Advanced Cervical Cancer (CC)
MVASI®, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, is approved to treat persistent, recurrent, or metastatic cancer of the cervix.
Ovarian Cancer (OC) MVASI®, in combination with carboplatin and paclitaxel, followed by Avastin alone, is used for the treatment of patients with advanced (Stage III or IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgery. MVASI®, in combination with paclitaxel, pegylated liposomal doxorubicin or topotecan, is approved to treat platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer in women who received no more than two prior chemotherapy treatments. MVASI®, either in combination with carboplatin and paclitaxel or with carboplatin and gemcitabine, followed by Avastin alone, is approved for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Indications Dosing Storage and Handling Prescribing Information Visit AmgenOncologyBiosimilars.com

FOR PATIENTS

GETTING TO KNOW MVASI®

 
WHAT IS MVASI® WHY AMGEN BIOSIMILARS SUPPORT ABOUT YOUR DIAGNOSIS

For Patients / Support

WHETHER YOU'RE A PATIENT OR A CAREGIVER, AMGEN IS HERE TO HELP

If you've been prescribed MVASI®, you might have questions about how your medicine may be covered by your insurance. That’s why we created Amgen SupportPlus—to support you in every way we can, so you can focus on what’s most important to you.

Amgen Assist 360™

Whatever type of insurance you have—even if you have none—your Amgen SupportPlus Representatives can help you understand how MVASI® may be covered, and refer you to programs that may be able to help you afford it, such as Amgen SupportPlus.

To speak to an Amgen Reimbursement Counselor call: 1-888-4ASSIST (888-427-7478) or visit AmgenAssist360.com.

Amgen® SupportPlus Representatives can help you understand:

INSURANCE COVERAGE

CO-PAY COSTS

DEDUCTIBLE COSTS

Amgen Assist 360™

REFERRALS TO RESOURCES FOR DAY-TO-DAY LIVING

We can help refer you to independent nonprofit organizations* that may provide you with community resources, one-on-one counseling services, and local support groups.

To speak to an Amgen SupportPlus Representatives, call 866-264-2778 or visit www.AmgenSupportPlus.com.

SupportPlus

  |   Co-Pay Program

Helping eligible patients save on
out-of-pocket costs
The Amgen SupportPlus Co-Pay Program is here to help eligible commercially insured patients pay for their out-of-pocket prescription costs.

  • Pay as little as $0 out-of-pocket for each dose or cycle
  • Can be applied to deductible, co-insurance, and co-payment†
  • No income eligibility requirement

Encourage your patients with private or commercial insurance to check eligibility and
enroll at www.AmgenSupportPlus.com/copay

‡ Terms, conditions, and program maximums apply. Other restrictions may apply. See www.AmgenSupportPlus.com/copay for full Terms and Conditions. This program is not open to patients receiving prescription reimbursement under any federal, state, or government-funded healthcare program. Not valid where prohibited by law.

Patient Brochure

TO LEARN MORE ABOUT YOUR CANCER AND MVASI®, DOWNLOAD THIS BROCHURE

Patient Brochure

Patient Brochure

*Eligibility for resources provided by independent nonprofit patient assistance programs is based on the nonprofit’s criteria. Amgen has no control over these programs and provides information as a courtesy only.

FOR INFORMATION SPECIFIC TO YOUR DIAGNOSIS, PLEASE MAKE A SELECTION BELOW

Links to the following organizations are provided for additional information and support, but should not be considered as an endorsement of MVASI® by these organizations.

VISIT THESE WEBSITES FOR MORE INFORMATION ABOUT COLORECTAL CANCER

Links to the following organizations are provided for additional information and support, but should not be considered as an endorsement of MVASI® by these organizations.

VISIT THESE WEBSITES FOR MORE INFORMATION ABOUT NON-SMALL CELL LUNG CANCER (NSCLC)

Links to the following organizations are provided for additional information and support, but should not be considered as an endorsement of MVASI® by these organizations.

VISIT THESE WEBSITES FOR MORE INFORMATION ABOUT GLIOBLASTOMA

Links to the following organizations are provided for additional information and support, but should not be considered as an endorsement of MVASI® by these organizations.

VISIT THESE WEBSITES FOR MORE INFORMATION ABOUT RENAL CELL CARCINOMA

Links to the following organizations are provided for additional information and support, but should not be considered as an endorsement of MVASI® by these organizations.

VISIT THESE WEBSITES FOR MORE INFORMATION ABOUT CERVICAL CANCER

Links to the following organizations are provided for additional information and support, but should not be considered as an endorsement of MVASI® by these organizations.

VISIT THESE WEBSITES FOR MORE INFORMATION ABOUT OVARIAN CANCER

foundation

betty-alen

ocra

Foundation for Women’s Cancer

VISIT THESE WEBSITES FOR MORE INFORMATION ABOUT VARIOUS CANCERS

Important Safety Information

Possible serious side effects

Everyone reacts differently to MVASI® therapy. So, it's important to know what the side effects are. Although some people may have a life-threatening side effect, most do not. Your doctor will stop treatment if any serious side effects occur. Be sure to contact your health care team if there are any signs of these side effects.

  • GI perforation. A hole that develops in your stomach or intestine. Symptoms include pain in your abdomen, nausea, vomiting, constipation, or fever
  • Abnormal passage in the body. This type of passage—known as a fistula—is an irregular connection from one part of the body to another and can sometimes be fatal
  • Wounds that don't heal. A cut made during surgery can be slow to heal or may not fully heal. MVASI® should not be used for at least 28 days before or after surgery and until surgical wounds are fully healed
  • Serious bleeding. This includes vomiting or coughing up blood; bleeding in the stomach, brain, or spinal cord; nosebleeds; and vaginal bleeding. If you recently coughed up blood or had serious bleeding, be sure to tell your doctor
  • Severe high blood pressure. Blood pressure that severely spikes or shows signs of affecting the brain. Blood pressure should be monitored every 2 to 3 weeks while on MVASI® and after stopping treatment
  • Kidney problems. These may be caused by too much protein in the urine and can sometimes be fatal
  • Infusion-related reactions. These were uncommon with the first dose (less than 3% of patients). 0.4% of patients had severe reactions. Infusion-related reactions include high blood pressure or severe high blood pressure that may lead to stroke, trouble breathing, decreased oxygen in red blood cells, a serious allergic reaction, chest pain, headache, tremors, and excessive sweating. Your doctor or nurse will monitor you for signs of infusion-related reactions
  • Severe stroke or heart problems. These may include blood clots, mini-stroke, heart attack, chest pain, and your heart may become too weak to pump blood to other parts of your body (congestive heart failure). These can sometimes be fatal
  • Nervous system and vision problems. Signs include headache, seizure, high blood pressure, sluggishness, confusion, and blindness

Side effects seen most often

In clinical studies across different types of cancer, some patients experienced the following side effects:

  • High blood pressure
  • Too much protein in the urine
  • Nosebleeds
  • Bleeding
  • Back pain
  • Headache
  • Taste change
  • Dry skin
  • Inflammation of the skin
  • Inflammation of the nose
  • Watery eyes

MVASI® is not for everyone

Talk to your doctor if you are:

  • Undergoing surgery. MVASI® should not be used for 28 days before or after surgery and until surgical wounds are fully healed
  • Pregnant or think you are pregnant. Data have shown that MVASI® may harm your unborn baby. Use birth control while on MVASI®. If you stop MVASI®, you should keep using birth control for 6 months before trying to become pregnant
  • Planning to become pregnant. Taking MVASI® could cause a woman’s ovaries to stop working and may impair her ability to have children
  • Breastfeeding. Breastfeeding while on MVASI® may harm your baby, therefore, women should not breastfeed during and for 6 months after taking MVASI®

For more information about your treatment or condition, talk to your doctor.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Amgen at 1-800-772-6436.

Please see full Product Information for additional Important Safety Information.

Indications

Metastatic Colorectal Cancer (mCRC)

MVASI® is approved to treat metastatic colorectal cancer (mCRC) for:

  • First- or second-line treatment in combination with intravenous fluorouracil-based chemotherapy
  • Second-line treatment when used with fluoropyrimidine-based (combined with irinotecan or oxaliplatin) chemotherapy after cancer progresses following a first-line treatment that includes MVASI®

MVASI® is not approved for use after the primary treatment of colon cancer that has not spread to other parts of the body.

Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

MVASI®, in combination with carboplatin and paclitaxel, is approved to treat advanced non-squamous non-small cell lung cancer (NSCLC) in people who have not received chemotherapy for their advanced disease.

Recurrent Glioblastoma (rGBM)

MVASI® is approved to treat recurrent glioblastoma in adults.

Metastatic Renal Cell Carcinoma (mRCC)

MVASI®, used with interferon alfa, is approved to treat metastatic kidney cancer (mRCC).

Advanced Cervical Cancer (CC)

MVASI®, in combination with paclitaxel and cisplatin or paclitaxel and topotecan, is approved to treat persistent, recurrent, or metastatic cancer of the cervix.

Ovarian Cancer (OC)

MVASI®, in combination with carboplatin and paclitaxel, followed by Avastin alone, is used for the treatment of patients with advanced (Stage III or IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer following initial surgery.

MVASI®, in combination with paclitaxel, pegylated liposomal doxorubicin or topotecan, is approved to treat platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer in women who received no more than two prior chemotherapy treatments.

MVASI®, either in combination with carboplatin and paclitaxel or with carboplatin and gemcitabine, followed by Avastin alone, is approved for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

MVASI® is a trademark of Amgen, Inc.

Important Safety Information

Possible serious side effects

Everyone reacts differently to MVASI® therapy. So, it's important to know what the side effects are. Although some people may have a life-threatening side effect, most do not. Your doctor will stop treatment if any serious side effects occur. Be sure to contact your health care team if there are any signs of these side effects.